Online citations, reference lists, and bibliographies.

Uncommon Thoracic Tumors

R. Rengan, Lara P. Bonner Millar, C. Thomas
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
Ranitidine side-effects.
D. Mattingly (1964)
10.1093/jnci/78.6.1053
Demographic patterns for mesothelioma in the United States.
R. Connelly (1987)
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.
C. Waldherr (2002)
10.1016/S0003-4975(03)00819-1
Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation.
S. Singhal (2003)
10.1097/JTO.0b013e3181e8f345
The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis
A. Fernandes (2010)
10.1016/0003-4975(95)00983-3
Surgical treatment for invasive thymoma, especially when the superior vena cava is invaded.
K. Yagi (1996)
10.1056/NEJM197801192980305
Myasthenia Gravis.
D. Drachman (1978)
10.1002/1097-0142(19930101)71:1<99::AID-CNCR2820710116>3.0.CO;2-6
Cytokeratins in normal thymus and thymic epithelial tumors
I. Fukai (1993)
10.1053/CTRV.1999.0159
Malignant thymoma: current status and future directions.
P. Lara (2000)
10.1002/cncr.11105
A 5‐decade analysis of 13,715 carcinoid tumors
I. Modlin (2003)
10.1097/00000478-199508000-00007
Long‐term Survival of Thymoma Patients by Histologic Pattern and Proliferative Activity
A. Pich (1995)
10.1001/archinte.1974.00320200184029
The spectrum of diseases associated with thymoma. Coincidence or syndrome?
J. V. Souadjian (1974)
10.1016/j.athoracsur.2010.01.026
Prognostic indicators after surgery for thymoma.
I. Okereke (2010)
10.1136/jcp.48.5.447
Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen.
N. Gilhus (1995)
10.1053/HUPA.2000.19294
Pulmonary atypical carcinoid: predictors of survival in 106 cases.
M. Beasley (2000)
10.1172/JCI117090
Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
A. Kubota (1994)
10.1016/S1010-7940(02)00085-4
Sleeve lobectomy for non-small cell lung cancer and carcinoids: results in 160 cases.
A. Terzi (2002)
10.1016/j.athoracsur.2012.03.004
The role of adjuvant radiation therapy for resected stage III thymoma: a population-based study.
B. Weksler (2012)
10.1097/00043426-199124000-00011
Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19).
U. Kees (1991)
10.1016/J.ATHORACSUR.2003.10.089
Bronchial carcinoid tumors: nodal status and long-term survival after resection.
G. Cardillo (2004)
Long-term outcomes of surgical treatment for pulmonary carcinoid tumors: 20 years' experience with 131 patients.
C. Zhong (2012)
10.1378/chest.111.1.106
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy.
B. Hoppe (2012)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1136/thx.44.6.455
Correlations between histological type, clinical behaviour, and prognosis in thymoma.
C. Ricci (1989)
10.1016/S0022-5223(19)33741-9
Primary mediastinal masses. A comparison of adult and pediatric populations.
K. Azarow (1993)
Karzinoide Tumoren des Dunndarms
S. Oberndorfer (1907)
10.1007/s12032-008-9100-0
Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report
X. Li (2009)
10.1016/0003-4975(91)90478-9
[Thymoma: results of 241 operated cases].
G. Maggi (1990)
10.1002/jso.2930500317
Thyroid and thymic malignancy following childhood irradiation.
M. O. Jensen (1992)
10.1007/BF01728801
Malignant mesothelioma of the pleura
A. Calavrezos (2005)
10.7326/0003-4819-99-5-736_1
Chemotherapy for malignant thymoma.
A. Chahinian (1983)
10.1016/j.lungcan.2008.03.013
Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
K. Yoh (2008)
10.1097/00000658-199608000-00016
Is postoperative radiotherapy for thymoma effective?
M. Haniuda (1996)
10.1136/THORAX.2003.009290
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112
M. Muers (2004)
10.1002/1097-0142(19890415)63:8<1493::AID-CNCR2820630807>3.0.CO;2-C
Chemotherapy of invasive thymoma. A retrospective study of 22 cases
N. Göldel (1989)
10.1002/cncr.10136
Diagnostic dilemmas in pulmonary cytology
J. Crapanzano (2001)
10.1002/cncr.23542
Bronchopulmonary neuroendocrine tumors
B. Gustafsson (2008)
10.1002/(SICI)1097-0339(199707)17:1<61::AID-DC13>3.0.CO;2-8
Thymoma mimicking thyroid papillary carcinoma: Another pitfall in fine‐needle aspiration
Y. Oertel (1997)
10.1378/chest.112.2.511
Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum.
D. Strollo (1997)
10.1097/00000478-199106000-00003
Neuroendocrine Tumors of the Lung With Proposed Criteria for Large‐Cell Neuroendocrine Carcinoma: An Ultrastructural, Immunohistochemical, and Flow Cytometric Study of 35 Cases
W. Travis (1991)
10.1016/J.ATHORACSUR.2007.04.076
Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.
D. Rice (2007)
10.1093/JJCO/HYL028
Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
E. Suzuki (2006)
10.1007/BF01608334
Thymic epithelial tumours: Evaluation of malignant grade by quantification of proliferating cell nuclear antigen and nucleolar organizer regions
H. Tateyama (2005)
10.1016/J.HLC.2006.08.010
Superior vena cava obstruction by tumour thrombus in invasive thymoma: diagnosis and surgical management.
I. Konstantinov (2007)
Carcinoid tumors and oat cell carcinomas of the thymus.
J. Rosai (1976)
10.1136/thx.39.8.617
Carcinoid tumours of the bronchus: a 33 year experience.
R. Hurt (1984)
10.1016/0003-4975(92)91139-Z
Bronchial carcinoid tumors: a retrospective analysis of 126 patients.
D. Harpole (1992)
10.1093/infdis/170.1.7
Thymic carcinoma with a defective Epstein-Barr virus encoding the BZLF1 trans-activator.
D. Patton (1994)
10.1210/JC.2004-1938
Whole-Body 11C-5-Hydroxytryptophan Positron Emission Tomography as a Universal Imaging Technique for Neuroendocrine Tumors : Comparison with Somatostatin Receptor Scintigraphy and Computed Tomography
H. Örlefors (2005)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1097/SLA.0b013e3181dd4ec4
Thymic Neuroendocrine Tumors: A SEER Database Analysis of 160 Patients
P. Gaur (2010)
Prognosis of thymic carcinoma: analysis of 16 cases.
H. K. Chang (1992)
10.1016/0360-3016(90)90056-P
Radiation therapy of invasive thymoma.
A. Arakawa (1990)
10.1111/j.1365-2559.1994.tb00594.x
Evaluation of a histogenetic classification for thymic epithelial tumours.
F. S. Ho (1994)
10.1200/JCO.2004.10.071
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2004)
10.1002/1097-0142(19940515)73:10<2491::AID-CNCR2820731007>3.0.CO;2-6
Thymoma. A retrospective study of 87 cases
H. S. Park (1994)
10.1016/S1010-7940(01)00634-0
Extended thymectomy in myasthenia gravis: a team-work of neurologist, thoracic surgeon and anaesthesist may improve the outcome.
A. Mussi (2001)
10.1136/thx.48.11.1135
How reliable is the diagnosis of lung cancer using small biopsy specimens? Report of a UKCCCR Lung Cancer Working Party.
J. Thomas (1993)
10.1016/S1010-7940(02)00665-6
Recurrence of stage I thymoma in sternum, 13 years after "complete" excision.
R. Reddy (2003)
10.1016/S1052-3359(02)00038-8
Surgical treatment of other bronchial tumors.
W. Scott (2003)
10.1093/annonc/mdr626
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
L. Schirosi (2012)
Primary carcinoid tumors of the lung: a role for radiotherapy.
H. Mackley (2006)
10.1016/s0022-5223(19)43412-0
Cases of thymoma at the Massachusetts General Hospital.
E. Wilkins (1966)
Radiographic chest assessment of lung injury following hemithorax irradiation for pleural mesothelioma.
P. Maasilta (1991)
Somatostatin (First of two parts)
S. Reichlin (1983)
10.1016/S0169-5002(00)00119-7
Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases.
A. Carretta (2000)
10.1002/PPUL.10249
Pediatric pulmonary carcinoid: a case report and review of the literature.
T. Moraes (2003)
Bronchopulmonary carcinoids: An analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties.
J. Soga (1999)
10.3109/02841869109092411
The role of interferons in the management of carcinoid tumors.
K. Oberg (1991)
10.1016/S0022-5223(97)70399-4
Recurrence of thymoma: analysis of clinicopathologic features, treatment, and outcome.
E. Ruffini (1997)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas.
J. Reubi (1990)
Genetic alteration in carcinoid tumors of the lung.
K. Sugio (2003)
Thymic carcinoma (report of 14 cases).
Z. Zhang (1997)
10.1002/cncr.23097
Secondary or concomitant neoplasms among adults diagnosed with acute lymphoblastic leukemia and treated according to the LALA‐87 and LALA‐94 trials
Emmanuelle Tavernier (2007)
10.1002/cncr.22404
Topoisomerase 2α plays a pivotal role in the tumor biology of stage IV thymic neoplasia
J. Liu (2007)
10.1002/(SICI)1097-0142(19990501)85:9<1871::AID-CNCR1>3.0.CO;2-Y
Nonsurgical management of malignant thymoma
M. Hejna (1999)
Thymoma--report of 71 cases and a review.
A. Verstandig (1992)
10.1016/J.ATHORACSUR.2003.08.004
Seeding of stage I thymoma into the chest wall 12 years after needle biopsy.
Hassan Kattach (2005)
10.1002/(SICI)1096-9098(199610)63:2<99::AID-JSO6>3.0.CO;2-J
Carcinoid tumors of the lung: immuno- and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically.
K. Kayser (1996)
10.1136/thx.22.3.193
Tumours of the thymus. A review of 88 operation cases.
Sellors Th (1967)
10.1016/S0936-6555(05)80540-0
Prevention of tumour seeding following thoracoscopy in mesothelioma by prophylactic radiotherapy.
E. Low (1995)
10.1200/JCO.2003.05.123
Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
K. Fizazi (2003)
10.1002/jso.23256
Long-term survival in thymic epithelial tumors: a single-center experience from China.
S. Shen (2013)
Pulmonary carcinoid and related tumours.
P. Hasleton (1997)
10.1007/BF03218097
Results from surgical treatment for thymoma. 43 years of experience.
T. Murakawa (2000)
Familial occurrence of thymoma.
A. Matani (1973)
[Acromegaly due to ectopic GH RH secretion by a bronchial carcinoid tumor: a case report].
Y. Lorcy (2002)
10.1016/0960-0760(90)90469-2
Somatostatin receptor imaging in vivo localization of tumors with a radiolabeled somatostatin analog
S. J. Lamberts (1990)
10.1016/j.athoracsur.2008.11.022
Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis.
R. Korst (2009)
10.1097/00005382-199601110-00007
Thymic Carcinoma: Case Reports and Review
P. Quagliano (1996)
10.3892/IJMM.1.5.823
p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors.
T. Oyama (1998)
10.1002/(SICI)1097-0142(19981015)83:8<1495::AID-CNCR4>3.0.CO;2-O
Thymoma: prognostic factors and treatment outcomes.
S. Gripp (1998)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1177/021849230201000213
Thymoma Associated with Pure Red-Cell Aplasia: Clinical Features and Prognosis
T. Murakawa (2002)
10.1016/S0140-6736(68)91528-6
Prostaglandins in amine-peptide-secreting tumours.
M. Sandler (1968)
10.1016/J.ATHORACSUR.2004.05.007
Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
R. Bueno (2004)
10.3816/CLC.2010.n.005
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
N. Katirtzoglou (2010)
10.1200/JCO.2011.40.3147
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Jennifer A. Chan (2012)
10.1016/j.ijrobp.2007.11.011
Intensity-modulated radiotherapy for resected mesothelioma: the Duke experience.
E. Miles (2008)
10.1177/021849230301100411
Predictors of Outcome for Myasthenia Gravis after Thymectomy
Y. Elmedany (2003)
10.7326/0003-4819-117-3-209
The Cushing syndrome induced by bronchial carcinoid tumors.
A. Limper (1992)
10.1016/S1010-7940(99)00052-4
Thymectomy for myasthenia gravis: a 27-year experience.
F. Venuta (1999)
Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
F. Bénard (1999)
10.1200/JCO.2005.04.1202
Neuroendocrine neoplasms of the lung: a prognostic spectrum.
H. Asamura (2006)
10.3109/02841869609109921
Radiosensitivity of mesothelioma cell lines.
A. Häkkinen (1996)
10.1016/S0003-4975(10)62558-1
Recurrence of thymoma: clinicopathological features, therapy, and prognosis.
Y. Monden (1985)
10.3109/02841869009090025
The role of preoperative radiotherapy for invasive thymoma.
K. Ohara (1990)
10.1002/1097-0142(19930715)72:2<394::AID-CNCR2820720214>3.0.CO;2-5
Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients. Part 2: Prognosis and staging
C. Boutin (1993)
10.1002/(SICI)1098-2264(200005)28:1<58::AID-GCC7>3.0.CO;2-2
MEN1 gene mutation analysis of high‐grade neuroendocrine lung carcinoma
L. Debelenko (2000)
10.1002/cncr.25367
Insulin‐like growth factor‐1 receptor and phosphorylated AKT‐serine 473 expression in 132 resected thymomas and thymic carcinomas
P. Zucali (2010)
10.1002/1097-0142(197204)29:4<1075::AID-CNCR2820290457>3.0.CO;2-O
Mediastinal endocrine neoplasm in patients with multiple endocrine adenomatosis. A previously unrecognized association
J. Rosai (1972)
10.1148/radiology.156.1.3923554
Malignant thymoma: role of radiation therapy in management.
C. Kersh (1985)
10.1200/JCO.2004.10.113
Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis.
P. Stroebel (2004)
10.1016/0167-8140(88)90043-6
Magnetic resonance imaging and high-resolution computed tomography in tumors of the lung and the mediastinum.
F. Casamassima (1988)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1016/0167-8140(90)90154-O
Role of radiation therapy in locally advanced thymoma.
A. Urgesi (1990)
10.1016/J.EJCTS.2004.04.041
Long-term survival and prognostic factors in thymic epithelial tumours.
F. Rea (2004)
10.1016/j.ijrobp.2009.02.016
Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease.
Jeffrey A. Forquer (2010)
10.1016/S0169-5002(00)80520-6
Therapeutic approach of carcinoid tumours of the lung.
M. Ruggieri (2000)
10.1016/J.HUMPATH.2003.07.013
Expression of matrix metalloproteinases 2 and 7 in tumor cells correlates with the World Health Organization classification subtype and clinical stage of thymic epithelial tumors.
E. Takahashi (2003)
10.1038/bjc.1992.200
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
O. Solheim (1992)
10.1097/JTO.0b013e31820ce2c7
Accuracy of Diagnostic Biopsy for the Histological Subtype of Malignant Pleural Mesothelioma
S. Kao (2011)
10.1097/JTO.0b013e3181b9eb85
Hemithoracic Radiotherapy After Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma: A Dosimetric Comparison of Two Well-Described Techniques
C. Hill-Kayser (2009)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.1002/cncr.24618
Postoperative radiation therapy after complete resection of thymoma has little impact on survival
T. Utsumi (2009)
10.1002/1097-0142(19910215)67:4<1025::AID-CNCR2820670427>3.0.CO;2-F
Thymic carcinoma. A clinicopathologic study of 60 cases
S. Suster (1991)
10.1148/RADIOLOGY.211.3.R99JN03657
Malignant pleural mesothelioma: US-guided histologic core-needle biopsy.
A. Heilo (1999)
10.1016/J.JTCVS.2007.07.049
Feasibility of multimodality therapy including extended resections in stage IVA thymoma.
J. Huang (2007)
10.1016/0003-4975(92)91391-L
Adjuvant radiotherapy after complete resection of thymoma.
M. Haniuda (1992)
10.1016/S0169-5002(98)00075-0
Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy.
M. Musi (1998)
Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity.
D. Dorfman (1997)
10.1016/S0022-5223(95)70029-3
Differential diagnosis of thymic carcinoma and lung carcinoma with the use of antibodies to cytokeratins.
I. Fukai (1995)
10.1016/0277-5379(89)90266-6
Radiation sensitivity of human lung cancer cell lines.
J. Carmichael (1989)
10.1016/S0169-5002(02)00080-6
Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark.
H. Skúladóttir (2002)
10.1002/IJC.10255
Histologic classification of thymic epithelial tumors: comparison of established classification schemes.
R. Rieker (2002)
Molecular genetic characterization of neuroendocrine lung cancer cell lines.
S. Lai (1995)
10.1097/JTO.0b013e3181f20ec4
Radiotherapy for thymic neoplasms.
C. Fuller (2010)
Tissue distribution of very late activation antigens-1/6 and very late activation antigen ligands in the normal thymus and in thymoma.
L. Ruco (1993)
10.1016/j.athoracsur.2012.02.009
Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma.
J. Friedberg (2012)
Postoperative radiotherapy for stage I thymoma: a prospective randomized trial in 29 cases.
H. Zhang (1999)
10.1002/1097-0142(19940715)74:2<606::AID-CNCR2820740212>3.0.CO;2-T
Thymoma: Histologic subclassification is an independent prognostic factor
L. Quintanilla-Martinez (1994)
10.1016/S0046-8177(96)90140-9
Cell kinetic study of thymic epithelial tumors using PCNA (PC10) and Ki-67 (MIB-1) antibodies.
W. Yang (1996)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1016/S0360-3016(01)02589-5
Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation.
A. Della Volpe (2002)
10.1182/BLOOD.V96.12.3872.H8003872_3872_3879
Thymomas alter the T-cell subset composition in the blood: a potential mechanism for thymoma-associated autoimmune disease.
V. Hoffacker (2000)
10.7326/0003-4819-99-2-189
Combination chemotherapy for malignant thymoma.
G. Daugaard (1983)
10.1093/JJCO/HYD108
Platinum-based chemotherapy with or without thoracic radiation therapy in patients with unresectable thymic carcinoma.
Y. Nakamura (2000)
10.1067/MTC.2002.119886
Bronchial carcinoid tumors: surgical management and long-term outcome.
P. Filosso (2002)
10.1097/00000478-199001000-00003
Thymic Carcinomas: Histopathological Varieties and Immunohistochemical Study
T. Kuo (1990)
10.1136/thx.49.4.357
Carcinoid tumours of the thymus.
D. Wang (1994)
10.1016/S1010-7940(02)00055-6
Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
P. Filosso (2002)
10.1007/BF02012403
Paediatric thymoma: Unusual occurrence in two siblings
W. Lam (2005)
10.1016/S0003-4975(02)03828-6
Adjuvant radiation therapy for stage II thymoma.
A. Mangi (2002)
10.1002/1097-0142(19861115)58:10<2290::AID-CNCR2820581022>3.0.CO;2-4
Flushing in the carcinoid syndrome and plasma kallikrein
K. Lucas (1986)
10.1002/1097-0142(19871215)60:12<2891::AID-CNCR2820601207>3.0.CO;2-6
A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A southwest oncology group study
R. Bukowski (1987)
10.1016/S0003-4975(00)01369-2
Original articlePrognostic factors in neuroendocrine lung tumors: a Spanish multicenter study
M. García-Yuste (2000)
10.2214/AJR.170.5.9574618
Evaluation of primary pulmonary carcinoid tumors using FDG PET.
J. Erasmus (1998)
10.1002/(SICI)1097-0339(199812)19:6<428::AID-DC5>3.0.CO;2-F
Fine‐needle aspiration of the mediastinum: A clinical, radiologic, cytologic, and histologic study of 42 cases
N. Shabb (1998)
10.1097/JTO.0b013e31815608d9
Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center
R. Flores (2007)
10.1586/14737140.5.2.231
Pemetrexed–cisplatin combination in mesothelioma
M. Reck (2005)
10.1042/bst0190180
Autoimmunity to acetylcholine receptors in myasthenia gravis.
A. Vincent (1991)
10.1016/0360-3016(91)90061-8
The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors.
K. Schupak (1991)
10.1016/J.LUNGCAN.2003.11.016
Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy.
L. Wirth (2004)
10.1016/S0003-4975(03)00555-1
Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan.
K. Kondo (2003)
10.1038/modpathol.3800534
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity
H. Yaziji (2006)
10.1016/S0002-9440(10)64426-4
Chromosome 6 suffers frequent and multiple aberrations in thymoma.
M. Inoue (2002)
10.1056/NEJM198505163122006
Association of Epstein-Barr virus with thymic carcinoma.
S. Leyvraz (1985)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1023/A:1012569909313
Experience in treatment of metastatic pulmonary carcinoid tumors.
D. Granberg (2001)
10.1136/thx.31.1.15
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients.
E. Butchart (1976)
10.1148/RADIOL.2232011131
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET.
E. Marom (2002)
10.1080/02841860410018575
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) Part I—General Overview
K. Öberg (2004)
10.1016/J.LUNGCAN.2003.12.010
Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report.
E. Kim (2004)
10.2214/ajr.142.1.73
CT of primary germ-cell tumors of the mediastinum.
R. Levitt (1984)
10.1378/chest.93.2.370
Atypical carcinoid of the lung. A distinct clinicopathologic entity.
T. Grote (1988)
10.1002/cncr.10588
Treatment and prognosis of thymic carcinoma
K. Ogawa (2002)
10.1016/S0022-5223(99)70469-1
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
10.1097/JTO.0b013e3181b6be57
Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas
G. Giaccone (2009)
10.1016/S1470-2045(05)70471-X
Survival from rare cancer in adults: a population-based study.
G. Gatta (2006)
10.1016/j.ijrobp.2011.09.027
Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.
K. Rosenzweig (2012)
10.1007/BF00737071
Thymoma and thymic carcinoma
M. Marino (1985)
10.1016/S1010-7940(01)00666-2
The multimodality treatment of thymic carcinoma.
M. Lucchi (2001)
10.1016/0003-4975(90)90087-M
Carcinoid tumors of the thymus.
G. Economopoulos (1990)
10.1016/S0039-6060(97)90090-8
Bronchial carcinoid--twenty years' experience defines a selective surgical approach.
T. Chughtai (1997)
Treatment and survival in diffuse malignant pleural mesothelioma; a study of 83 cases from the Massachusetts General Hospital.
M. Huncharek (1996)
10.1016/S1010-7940(01)01091-0
Prognostic factors in thymic epithelial neoplasms.
A. Ríos (2002)
10.1016/S0002-9440(10)65166-8
DNA copy number losses in human neoplasms.
S. Knuutila (1999)
10.1016/0360-3016(82)90379-0
Radiation therapy in the management of patients with mesothelioma.
W. Gordon (1980)
10.1016/0003-4975(91)90848-K
Primary cysts and tumors of the mediastinum.
A. Cohen (1991)
10.1016/S0022-5223(19)34645-8
A twenty-five-year follow-up of ninety-three resected typical carcinoid tumors of the lung
A. Schreurs (1992)
10.1002/jso.2930540311
Treatment of invasive thymoma with pleural dissemination.
Y. Ichinose (1993)
10.1002/1097-0142(19860315)57:6<1101::AID-CNCR2820570606>3.0.CO;2-A
Chemotherapy of malignant thymoma. Case report and review of the literature
E. Hu (1986)
10.1002/1097-0142(197408)34:2<389::AID-CNCR2820340224>3.0.CO;2-Z
Thymomas: Clinicopathologic features, therapy, and prognosis
M. Batata (1974)
Image and diagnosis. Carcinoid tumor of the lung.
W. West (2002)
10.1016/S0022-5223(19)38842-7
Bronchial carcinoids: Review of 124 cases
B. McCaughan (1985)
10.1016/J.IJROBP.2007.02.047
Influence of radiotherapy technique and dose on patterns of failure for mesothelioma patients after extrapleural pneumonectomy.
A. Allen (2007)
10.1200/JCO.1993.11.8.1559
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
A. Chahinian (1993)
10.1016/S0003-4975(00)02251-7
Giant bronchial carcinoid tumors: a multidisciplinary approach.
Stefan Fischer (2001)
10.1378/chest.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1016/J.BRACHY.2004.11.003
A pilot trial of high-dose-rate intraoperative radiation therapy for malignant pleural mesothelioma.
K. Rosenzweig (2005)
Novel t(15;19)(q15;p13) chromosome abnormality in a thymic carcinoma.
I. Kubonishi (1991)
10.1067/MSY.2001.110426
Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years.
H. Nave (2001)
10.1016/S0003-4975(10)63114-1
Thymoma: a continuing survey at the Massachusetts General Hospital.
E. Wilkins (1979)
10.1002/JCA.20061
Prethymectomy plasmapheresis in myasthenia gravis.
J. Yeh (2005)
10.1016/s0022-5223(19)37426-4
Management of patients with malignant thymoma.
D. Cohen (1984)
10.1016/S0003-4975(98)00083-6
Operative risk and prognostic factors of typical bronchial carcinoid tumors.
X. Ducrocq (1998)
10.5555/uri:pii:S0022522394704449
Treatment and prognosis in bronchial carcinoids involving regional lymph nodes.
N. Martini (1994)
10.1097/COC.0b013e318042d566
Adjuvant Radiotherapy for Thymic Epithelial Tumor: Treatment Results and Prognostic Factors
Y. Kundel (2007)
10.1038/sj.bjc.6690773
Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience
A. Berruti (1999)
10.1378/CHEST.112.4_SUPPLEMENT.296S
Controversies in the management of malignant thymoma.
L. Kohman (1997)
10.1016/0003-4975(90)90185-9
Analysis of prognostic factors and clinicopathological staging of thymoma.
E. Pescarmona (1990)
10.1111/j.1440-1827.1994.tb02600.x
Thymic carcinoma: proposal for pathological TNM and staging.
R. Tsuchiya (1994)
10.1038/sj.bjc.6602245
Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression
A. Couvelard (2005)
10.1378/chest.65.1.114
Response of thymoma to steroids.
J. D. Green (1974)
10.1007/BF00194697
Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21
Y. Hayashi (1995)
10.1053/STCS.2002.32061
Surgical techniques for pulmonary metastasectomy.
V. Rusch (2002)
10.1016/S0003-4975(01)03607-4
Primary thymic carcinoma.
Hung-Chang Liu (2002)
10.1016/0360-3016(90)90724-X
The role of radiotherapy in the management of invasive thymoma
E. Hug (1990)
10.1634/THEONCOLOGIST.6-3-239
Thymoma: update for the new millennium.
S. B. Johnson (2001)
10.1179/oeh.2004.10.1.26
Malignant Pleural Mesothelioma—An Update
D. Stewart (2004)
10.1378/CHEST.124.1.141
A clinicopathologic study of 12 neuroendocrine tumors arising in the thymus.
O. Tiffet (2003)
10.1158/1078-0432.CCR-09-0644
Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas
N. Girard (2009)
10.1016/0026-0495(85)90009-5
Increased dopamine production in patients with carcinoid tumors.
J. Feldman (1985)
10.1016/S0954-6111(89)80201-X
Typical and atypical bronchial carcinoids.
M. Torre (1989)
10.1200/jco.1984.2.11.1255
Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor.
P. Engstrom (1984)
10.1016/0277-5379(84)90036-1
Invasive carcinoma of the thymus. A multicenter retrospective review of 56 cases.
R. Arriagada (1984)
10.1002/cncr.10373
Postoperative radiotherapy for patients with completely resected thymoma
K. Ogawa (2002)
10.1378/CHEST.112.4_SUPPLEMENT.272S
Multimodality therapy for malignant pleural mesothelioma.
D. Sugarbaker (1997)
10.1002/1097-0142(19810401)47:7<1752::AID-CNCR2820470705>3.0.CO;2-C
Treatment of invasive or metastatic thymoma: Report of eleven cases
A. Philippe Chahinian (1981)
10.1016/S0003-4975(00)01369-2
Prognostic factors in neuroendocrine lung tumors: a Spanish Multicenter Study. Spanish Multicenter Study of Neuroendocrine Tumors of the Lung of the Spanish Society of Pneumonology and Thoracic Surgery (EMETNE-SEPAR).
M. García-Yuste (2000)
10.1093/oxfordjournals.jjco.a039779
Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
F. Oshita (1995)
10.1097/JTO.0b013e31821c4203
Computed Tomography Findings Predicting Invasiveness of Thymoma
E. Marom (2011)
10.1016/S0165-4608(03)00098-0
Deletion (6)(p22p25) is a recurrent anomaly of thymoma: report of a second case and review of the literature.
C. Herens (2003)
10.1016/S0147-0272(77)80006-8
Primary tumors and cysts of the mediastinum.
H. Oldham (1967)
10.1378/chest.08-2482
Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms.
T. Khoury (2009)
10.2214/AJR.176.2.1760433
Malignant thymic epithelial tumors: CT-pathologic correlation.
K. Jung (2001)
Cigarette smoking, asbestos exposure, and malignant mesothelioma.
J. Muscat (1991)
10.1097/00000658-199807000-00015
Thymic carcinoids in multiple endocrine neoplasia type 1.
B. Teh (1998)
CD5 expression in thymic carcinoma.
T. Hishima (1994)
10.1016/0167-8140(92)90227-L
Aggressive treatment of intrathoracic recurrences of thymoma.
A. Urgesi (1992)
10.1200/JCO.2007.15.4377
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.
J. Yao (2008)
10.1196/annals.1405.018
Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms.
P. Stroebel (2008)
10.1055/S-2005-837539
Carcinoid tumors of the lung and multimodal therapy.
D. Divisi (2005)
10.1111/j.1600-0404.1989.tb03866.x
Increased incidence of thymoma in Chinese myasthenia gravis: possible relationship with Epstein‐Barr virus
R. Teoh (1989)
10.1002/1097-0142(19910815)68:4<706::AID-CNCR2820680407>3.0.CO;2-H
Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma
P. Macchiarini (1991)
10.1093/AJCP/111.2.235
Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma.
H. Tateyama (1999)
10.1002/1097-0142(20010601)91:11<2010::AID-CNCR1226>3.0.CO;2-2
Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma
Patrick J. Loehrer (2001)
10.1148/RADIOGRAPHICS.19.3.G99MA11707
Thoracic carcinoids: radiologic-pathologic correlation.
M. L. Rosado de Christenson (1999)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1097/JTO.0b013e3181f20ea2
Technical advances of radiation therapy for thymic malignancies.
D. Gomez (2010)
10.1007/s002689900029
Pulmonary and Thymic Carcinoid Tumors
M. Dusmet (1996)
10.1136/thorax.55.9.731
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems
J. Edwards (2000)
10.1002/IJC.11099
Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies.
E. Engels (2003)
10.1016/0002-9343(86)90583-8
Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors.
J. Feldman (1986)
10.1097/JTO.0b013e3181f21114
Targeted Therapy for Advanced Thymic Tumors
A. Rajan (2010)
10.1007/s00277-003-0635-z
B-cell lymphopenia and hypogammaglobulinemia in thymoma patients
L. Montella (2003)
10.1097/00000478-200106000-00015
Thyroid Transcription Factor-1 Distinguishes Metastatic Pulmonary From Well-Differentiated Neuroendocrine Tumors of Other Sites
A. Oliveira (2001)
10.1007/S002680020021
Treatment of Malignant Mesothelioma
M. Jaklitsch (2001)
10.1016/S0046-8177(96)90289-0
Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness.
F. Chen (1996)
10.1097/00130404-200311000-00008
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
10.1186/1471-2482-2-3
Clinical and immunohistochemical study of eight cases with thymic carcinoma
M. Tomita (2002)
10.1016/0360-3016(81)90481-8
Computerized tomography scanning and the planning of high-dose radiotherapy for pleural mesothelioma: a report of five patients.
P. Bricout (1981)
10.1016/j.ijrobp.2009.02.067
Permanent iodine-125 interstitial planar seed brachytherapy for close or positive margins for thoracic malignancies.
S. Mutyala (2010)
10.1002/jso.2930540409
Predictors of survival following surgical resection of thymoma.
J. A. McCart (1993)
Chemotherapy of invasive or metastatic thymoma: report of 11 cases.
A. Fornasiero (1984)
10.1378/CHEST.117.6.1787
Diagnosis and treatment of mediastinal tumors by thoracoscopy.
L. M. Cirino (2000)
Primary pleural thymoma.
Shih Df (1997)
10.1136/thx.48.6.632
Percutaneous needle biopsy of the mediastinum: review of 94 procedures.
B. Morrissey (1993)
10.1016/0360-3016(91)90054-8
Deterioration in lung function following hemithorax irradiation for pleural mesothelioma.
P. Maasilta (1991)
10.1002/cncr.10665
New WHO histologic classification predicts prognosis of thymic epithelial tumors
G. Chen (2002)
10.1200/JCO.1997.15.9.3093
Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial.
P. Loehrer (1997)
10.1016/S0003-4975(02)04474-0
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
J. Friedberg (2003)
10.1016/S0039-6109(16)40093-9
Thymoma: factors influencing prognosis.
P. E. Bernatz (1973)
Fine needle aspiration cytology of thymic tumors.
S. Dahlgren (1983)
10.1097/JTO.0b013e3181c0a7ff
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease: An Observational Pilot Study
H. Yildirim (2009)
10.1016/S0002-9440(10)65653-2
Typical and atypical carcinoid tumors of the lung are characterized by 11q deletions as detected by comparative genomic hybridization.
A. Walch (1998)
10.1016/S0002-9610(99)80107-X
Hepatic resection for metastatic neuroendocrine carcinomas.
F. Que (1995)
10.1016/S0003-4975(98)00378-6
Multicenter VATS experience with mediastinal tumors.
T. L. Demmy (1998)
10.1378/chest.103.4_Supplement.382S
Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma.
V. Rusch (1993)
10.1016/J.LUNGCAN.2003.08.017
Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience.
L. Schrevens (2004)
10.1111/j.1365-2559.1995.tb00269.x
Thymoma--a study of 60 cases in Singapore.
P. Tan (1995)
10.1148/radiology.168.3.3136511
Stage III thymoma: results of postoperative radiation therapy.
J. Krueger (1988)
Subcutaneous tumor growth complicating the positioning of Denver shunt and intrapleural port-à-cath in mesothelioma patients.
B. van Ooijen (1992)
10.1016/j.athoracsur.2009.05.019
Multimodality therapy for patients with invasive thymoma disseminated into the pleural cavity: the potential role of extrapleural pneumonectomy.
Y. Ishikawa (2009)
10.1200/JCO.1988.6.3.536
Undifferentiated epithelial-rich invasive malignant thymoma: complete response to cisplatin, vinblastine, and bleomycin therapy.
C. Dy (1988)
10.1016/1010-7940(93)90033-8
Clinical features and therapy of "typical" and "atypical" bronchial carcinoid tumors (grade 1 and grade 2 neuroendocrine carcinoma).
F. Smolle-Jüttner (1993)
10.1016/1010-7940(93)90140-7
Diagnosis and treatment of bronchial carcinoid tumors: clinical and pathological review of 120 operated patients.
P. Vadász (1993)
10.1016/J.IJROBP.2007.07.2370
Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy.
J. Krayenbuehl (2007)
10.1016/j.athoracsur.2012.01.014
Thymic carcinoma: outcomes after surgical resection.
I. Okereke (2012)
10.1016/S0360-3016(02)04151-2
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
10.1080/00313029800169056
Thymic carcinoma: Spectrum of differentiation and histologic types
S. Suster (1998)
10.1016/S0002-9440(10)64536-1
Recurrent genetic aberrations in thymoma and thymic carcinoma.
A. Zettl (2000)
10.1016/S0360-3016(01)02656-6
Postoperative radiotherapy in thymic carcinoma: treatment results and prognostic factors.
H. C. Hsu (2002)
10.1148/RADIOLOGY.204.3.9280272
Invasive thymoma: treatment with postoperative radiation therapy.
D. Latz (1997)
10.1038/sj.onc.1201034
Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors
A. Abdollahi (1997)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1378/chest.59.3.324
Diagnosis of mediastinal tumors. X-ray manifestations of redundant pericardial fat.
T. V. Thomas (1971)
10.1097/00000478-197706000-00002
Squamous cell carcinoma of the thymus. An analysis of eight cases
Y. Shimosato (1977)
10.1097/00005792-200103000-00005
Infections in Patients with Immunodeficiency with Thymoma (Good Syndrome): Report of 5 Cases and Review of the Literature
P. Tarr (2001)
10.1016/J.LUNGCAN.2005.03.006
Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging.
H. Steinert (2005)
10.1016/0167-8140(94)01493-M
Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer.
D. Cowen (1995)
10.1016/S0022-5223(96)70265-9
Prognostic factors and long-term results after thymoma resection: a series of 307 patients.
J. Régnard (1996)
Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.
Moertel Cg (1979)
10.1016/0360-3016(95)00079-E
Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. The FNCLCC trialists. Fédération Nationale des Centres de Lutte Contre le Cancer.
F. Mornex (1995)
10.1016/0899-7071(94)00041-A
Squamous cell carcinoma of the thymus with paraneoplastic hypercalcemia.
J. M. Negron-Soto (1995)
10.1038/bjc.1997.561
High frequency of p53 protein expression in thymic carcinoma but not in thymoma.
N. Hino (1997)
10.6004/JNCCN.2009.0050
NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.
O. Clark (2009)
10.1182/BLOOD.V100.1.159
Paraneoplastic myasthenia gravis correlates with generation of mature naive CD4(+) T cells in thymomas.
P. Stroebel (2002)
10.1016/S0003-4975(97)00629-2
Multimodality treatment of thymoma: a prospective study.
F. Venuta (1997)
10.1097/00000658-199910000-00012
Clinical and pathologic predictors of survival in patients with thymoma.
K. Wilkins (1999)
10.1007/BF01791148
Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: A preliminary report
R. Liu (2005)
10.1002/1097-0142(197601)37:1<229::AID-CNCR2820370133>3.0.CO;2-2
Thymoma. A clinical and pathological study of 65 cases
W. Salyer (1976)
10.1002/1097-0142(197607)38:1<49::AID-CNCR2820380109>3.0.CO;2-6
Chemotherapy of invasive thymoma
B. Boston (1976)
10.1002/1097-0142(19860801)58:3<765::AID-CNCR2820580326>3.0.CO;2-S
Thymomas: A review of 169 cases, with particular reference to results of surgical treatment
G. Maggi (1986)
10.1002/(SICI)1097-0142(19990201)85:3<600::AID-CNCR10>3.0.CO;2-W
Genetic changes in the spectrum of neuroendocrine lung tumors
N. Onuki (1999)
10.1097/JTO.0b013e3181f1f63f
The Autoimmune Regulator AIRE in Thymoma Biology: Autoimmunity and Beyond
A. Marx (2010)
10.1016/S0039-6109(16)41736-6
The APUD cell system and its neoplasms: observations on the significance and limitations of the concept.
V. Gould (1979)
10.1016/S0022-5223(98)70273-9
Thymic carcinoma: current staging does not predict prognosis.
D. Blumberg (1998)
10.1016/S0003-4975(00)01140-1
Prognostic relevance of Masaoka and Müller-Hermelink classification in patients with thymic tumors.
D. Lardinois (2000)
10.1038/bjc.1982.15
Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment.
J. Peto (1982)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1067/MTC.2002.125817
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
T. T. Lee (2002)
10.1200/JCO.2009.22.8585
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
D. Bushnell (2010)
10.1378/CHEST.119.6.1647
Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature.
G. Fink (2001)
10.1097/00000478-199202000-00006
Thymomas Presenting as Pleural Tumors: Report of Eight Cases
C. Moran (1992)
[CD40 as a mediator of proliferation in normal ans neoplastic thymic epithelium].
A. Schultz (1996)
10.1097/00000658-199709000-00012
Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis.
G. Bulkley (1997)
10.1016/0360-3016(90)90126-5
The incidence of myelitis after irradiation of the cervical spinal cord.
R. Marcus (1990)
10.1016/j.athoracsur.2009.12.041
Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
B. Balduyck (2010)
10.3816/CLC.2009.n.033
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
Brad E Wilcox (2009)
10.1067/MTC.2002.124389
Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors.
M. Tomita (2002)
10.1097/JTO.0b013e3181653c8c
Pathologic Radioresponse of Preoperatively Irradiated Invasive Thymomas
T. Onuki (2008)
10.1002/1097-0142(197404)33:4<1196::AID-CNCR2820330445>3.0.CO;2-0
Primary mediastinal choriocarcinoma in the male
E. Sickles (1974)
10.1245/ASO.2003.09.019
Update in Pulmonary Carcinoid Tumors: A Review Article
R. Hage (2003)
10.1200/JCO.1999.17.9.2737
Treatment of invasive thymoma with single-agent ifosfamide.
M. Highley (1999)
10.1016/0003-4975(91)90999-7
J. Maxwell Chamberlain Memorial Paper. Role of staging in prognosis and management of thymoma.
E. Wilkins (1991)
10.1002/bjs.1800590708
The role of radiotherapy in the management of malignant thymoma
C. R. Penn (1972)
10.1016/S0025-6196(12)60697-1
Primary mediastinal neoplasms (other than thymoma).
O. A. Hoffman (1993)
10.1210/JCEM.86.2.7194
Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
G. Kaltsas (2001)
10.1016/S0360-3016(03)00287-6
Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma.
S. Yajnik (2003)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
Differential diagnosis of thymic tumors using a combination of 11C-methionine PET and FDG PET.
M. Sasaki (1999)
10.1016/j.ctrv.2012.11.005
Thymoma and thymic carcinoma in the target therapies era.
A. Lamarca (2013)
10.1016/0167-8140(91)90078-U
Post-operative radiotherapy in invasive thymoma.
M. Jackson (1991)
10.1016/S0002-8703(97)70053-X
Cardiovascular complications of malignant carcinoid disease.
A. Anderson (1997)
10.1097/00000478-200005000-00014
CD70 expression in thymic carcinoma.
T. Hishima (2000)
10.1016/S0003-4975(02)03547-6
Primary neuroendocrine tumors of the thymus.
R. Chaer (2002)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1016/0003-4975(94)00630-P
Carcinoid tumors of the lung: do atypical features require aggressive management?
C. Marty-Ané (1995)
10.1038/sj.bjc.6605740
Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience
P. Stroebel (2010)
Thymomas: clinical-pathological correlations.
M. Lucchi (2006)
A 25-year thymoma treatment review.
B. Whooley (2000)
10.1001/ARCHNEUR.57.4.527
Autoantibodies in thymoma-associated myasthenia gravis with myositis or neuromyotonia.
Å. Mygland (2000)
10.1200/JCO.2007.15.9020
Activity of sunitinib in patients with advanced neuroendocrine tumors.
Matthew H. Kulke (2008)
10.1002/1097-0142(19801001)46:7<1523::AID-CNCR2820460705>3.0.CO;2-#
Combination chemotherapy in invasive thymoma. Role of COPP
W. Evans (1980)
10.1378/CHEST.06-0711
The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules.
C. Daniels (2007)
10.1002/ana.1017
Mature, long‐lived CD4+ and CD8+ T cells are generated by the thymoma in myasthenia gravis
C. Buckley (2001)
10.1097/00004728-199105000-00015
CT findings in primary thymic carcinoma.
J. Lee (1991)
Human TRK proto-oncogene maps to chromosome 1q32-q41.
M. Miozzo (1990)
10.2152/JMI.59.225
The utility of FDG-PET in the diagnosis of thymic epithelial tumors.
H. Otsuka (2012)
10.1016/S0003-4975(10)64915-6
Carcinoid tumors of the lung.
N. Okike (1976)
10.1007/s005950170021
Elevated Serum Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Levels in Patients with Thymic Epithelial Neoplasms
H. Sasaki (2001)
10.1200/JCO.1994.12.7.1484
Prognostic factors and outcome of incompletely resected invasive thymoma following radiation therapy.
I. Ciernik (1994)
10.1016/j.jtcvs.2009.02.046
Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.
T. R. Tilleman (2009)
Epstein-Barr virus genome in thymoma and thymic lymphoid hyperplasia.
L. McGuire (1988)
10.5761/ATCS.OA.10.01572
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience.
T. Yan (2011)
10.1056/NEJMoa1009290
Everolimus for advanced pancreatic neuroendocrine tumors.
J. Yao (2011)
10.7326/0003-4819-129-2-199807150-00006
A Multidisciplinary Approach to Therapy for Unresectable Malignant Thymoma
D. Shin (1998)
10.1080/028418698430421
Radioresponse of thymomas verified with histologic response.
K. Ohara (1998)
10.1016/J.IJROBP.2006.01.052
Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.
J. Chang (2006)
10.1097/00000478-199808000-00003
Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.
W. Travis (1998)
10.1002/(SICI)1096-9098(199902)70:2<95::AID-JSO6>3.0.CO;2-8
Primary tumors of the mediastinum.
B. Whooley (1999)
10.1148/rg.302095131
Clinical and radiologic review of the normal and abnormal thymus: pearls and pitfalls.
F. Nasseri (2010)
10.1016/J.LUNGCAN.2003.09.022
Multimodal management of stages III-IVa malignant thymoma.
S. Bretti (2004)
10.1309/3PDN-PMT5-EQTM-H0CD
Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases.
C. Moran (2000)
10.1200/JCO.1988.6.11.1722
Invasive thymoma: the role of mediastinal irradiation following complete or incomplete surgical resection.
W. Curran (1988)
10.1002/1097-0142(19810915)48:6<1315::AID-CNCR2820480611>3.0.CO;2-2
A complete response in metastatic malignant thymoma to cis‐platinum, doxorubicin and cyclophosphamide: A case report
M. Campbell (1981)
10.1002/1097-0142(19850301)55:5<1074::AID-CNCR2820550524>3.0.CO;2-T
Thymoma. A comparative study of clinical stages, histologic features, and survival in 200 cases
J. Verley (1985)
10.1007/BF02939369
Substance p secretion by carcinoid tumours
P. Skrabanek (1978)
DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies.
S. Knuutila (1998)
10.1016/0140-6736(92)91235-Z
Ondansetron in carcinoid syndrome
A. J. Platt (1992)
10.1093/annonc/mds147
Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas.
T. Mimae (2012)
10.1016/S0003-4975(10)62751-8
Primary anterior mediastinal tumors in children and adults.
B. Mullen (1986)
10.1016/j.athoracsur.2007.08.051
Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors.
C. Wright (2008)
10.1093/ANNONC/MDM501
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
10.1016/J.JTCVS.2005.07.026
Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size.
C. Wright (2005)
10.1200/JCO.1994.12.6.1164
Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.
P. Loehrer (1994)
10.1053/j.semtcvs.2009.07.001
Photodynamic therapy as an innovative treatment for malignant pleural mesothelioma.
J. Friedberg (2009)
10.1016/j.athoracsur.2010.01.038
Assessment of robotic thymectomy using the Myasthenia Gravis Foundation of America Guidelines.
S. Goldstein (2010)
10.1200/JCO.2005.23.16_SUPPL.7068
Phase II study of gefitinib treatment in advanced thymic malignancies
A. Kurup (2005)
10.1056/NEJM200406173502523
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
P. Stroebel (2004)
10.1016/J.IJROBP.2003.11.021
Thymic carcinoma: state of the art review.
T. Eng (2004)
10.1016/S1010-7940(00)00493-0
Long-term outcome after resection for bronchial carcinoid tumors.
M. Ferguson (2000)
Tumors of the thymus
A. Levene (1990)
10.1016/j.lungcan.2010.01.015
Surgical treatment of bronchial carcinoid tumors: a single-center experience.
T. Machuca (2010)
10.1016/0003-4975(95)00669-C
Thymoma: a multivariate analysis of factors predicting survival.
D. Blumberg (1995)
10.1002/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R
Follow‐up study of thymomas with special reference to their clinical stages
A. Masaoka (1981)
10.1002/1097-0142(19910701)68:1<30::AID-CNCR2820680106>3.0.CO;2-4
Chemotherapy for invasive thymoma. A 13‐year experience
Adriano Fornasiero (1991)
64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
C. Anderson (2001)
10.1200/JCO.1996.14.3.814
Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
G. Giaccone (1996)
10.1016/S0003-4975(10)63498-4
Tumors of the thymus and thymic region: I. Clinicopathological studies on thymomas.
N. Bergh (1978)
Changes in hair pigmentation associated with cancer chemotherapy.
Jaffrey Is (1980)
10.1016/0360-3016(87)90173-8
Technique for external beam treatment for mesothelioma.
G. Kutcher (1987)
10.1016/S0022-5223(96)70409-9
Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases.
V. de Montpréville (1996)
10.1093/ajcp/104.4.375
p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study.
H. Tateyama (1995)
10.1016/S0002-9610(99)80210-4
Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization.
D. Diaco (1995)
10.1097/00000478-198210000-00003
Primary thymic carcinomas
M. Wick (1982)
10.1210/jcem.82.5.3944
Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1.
Q. Dong (1997)
10.1016/S0003-4975(10)62059-0
Primary cysts and neoplasms of the mediastinum: recent changes in clinical presentation, methods of diagnosis, management, and results.
R. Davis (1987)
10.4161/cbt.10.5.12616
Extrapleural pneumonectomy, photodynamic therapy and intensity modulated radiation therapy for the treatment of malignant pleural mesothelioma
K. Du (2010)
10.1016/J.IJROBP.2005.03.041
Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma.
V. Gupta (2005)
10.1007/S11864-000-0047-4
Malignant pleural mesothelioma
H. Kindler (2000)
10.1016/s0022-5223(19)35673-9
Thymoma: results with complete resection and adjuvant postoperative irradiation in 141 consecutive patients.
K. Nakahara (1988)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1200/JCO.1999.17.7.2280
Thymoma: state of the art.
C. Thomas (1999)
10.1038/sj.bjc.6605731
A phase II trial of dose-dense chemotherapy, followed by surgical resection and/or thoracic radiotherapy, in locally advanced thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9606)
H. Kunitoh (2010)
10.1002/1097-0142(197801)41:1<117::AID-CNCR2820410118>3.0.CO;2-V
Radiation therapy control of nine patients with malignant thymoma
R. Marks (1978)
10.1002/cncr.25851
Adjuvant radiotherapy for completely resected stage 2 thymoma
A. Berman (2011)
10.1002/1097-0142(196509)18:9<1131::AID-CNCR2820180914>3.0.CO;2-F
Pathology and clinical behavior of thymomas. A survey of 51 cases
M. Legg (1965)
10.1002/1097-0142(20000625)90:3<148::AID-CNCR3>3.0.CO;2-9
A review of cytologic findings in neuroendocrine carcinomas including carcinoid tumors with histologic correlation
S. A. Nicholson (2000)
10.1016/0360-3016(84)90050-6
Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.
B. Hilaris (1984)
10.5555/uri:pii:0740257091900654
Neuroendocrine neoplasms of the mediastinum.
M. Wick (1991)
10.1016/S0360-3016(02)03796-3
Outcomes and patterns of failure in bronchial carcinoid tumors.
B. Kaplan (2003)
10.1097/JTO.0b013e3181ed0489
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
10.1016/0360-3016(92)90911-Z
Thymoma: treatment and prognosis.
A. Pollack (1992)
10.1016/S0003-4975(03)01194-9
Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification.
M. Mezzetti (2003)
10.1016/j.jtcvs.2009.10.024
Type B thymoma: is prognosis predicted only by World Health Organization classification?
H. Kim (2010)
10.1016/S0003-4975(98)01063-7
Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study in 15 patients.
I. Fukai (1999)
10.1002/(SICI)1097-0029(19970901)38:5<468::AID-JEMT2>3.0.CO;2-E
Typical and atypical lung carcinoids: clinical and morphological diagnosis.
C. Mendonça (1997)
10.1038/bjc.1996.157
PET imaging of primary mediastinal tumours.
K. Kubota (1996)
10.1126/science.1200609
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Y. Jiao (2011)
10.1111/j.1365-2141.1991.tb08125.x
The role of interferons in the management of carcinoid tumours
K. Öberg (1991)
10.1097/JTO.0b013e31818b06e3
The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho-Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM Classification for Lung Cancer
W. Travis (2008)
10.1016/J.EJCTS.2004.03.043
Thymic carcinoma. Clinical institutional experience with 15 patients.
S. Takeda (2004)
10.1007/s002689900137
Progression of Metastases and Symptom Improvement from Laparotomy in Midgut Carcinoid Tumors
Charlie Makridis (1996)
10.1097/01.COC.0000020584.56294.72
Atypical Thymic Carcinoid and Malignant Somatostatinoma in Type I Multiple Endocrine Neoplasia Syndrome: Case Report
F. C. Lin (2003)
10.1016/0360-3016(79)90042-7
The management of malignant thymoma with radiation therapy
L. Ariaratnam (1977)
10.1007/s00432-001-0319-9
Epidermal growth factor receptor expression in invasive thymoma
J. Henley (2002)
10.1093/ejcts/ezs529
Clinicopathological features of thymic carcinomas and the impact of histopathological agreement on prognostical studies.
A. Roden (2013)
10.1016/J.IJROBP.2004.05.013
Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients.
G. Zhu (2004)
10.1093/ejcts/ezs527
The utility of [18F]-fluorodeoxyglucose positron emission tomography-computed tomography in thymic epithelial tumours.
K. Fukumoto (2012)
Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
M. de Jong (2001)
10.1002/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2
An analysis of 8305 cases of carcinoid tumors
I. Modlin (1997)
10.1002/cncr.23034
Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma
L. Greillier (2007)
10.1007/BF02743578
Radiotherapy for invasive thymoma and thymic carcinoma
Ramona Mayer (2007)
10.1002/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO;2-D
Thymoma. A clinicopathologic review
J. Lewis (1987)
10.1002/1097-0142(196906)23:6<1423::AID-CNCR2820230625>3.0.CO;2-M
Recurrence of noninvasive thymomas. Report of Four Cases and Review of Literature
R. Fechner (1969)
10.1002/(SICI)1097-0142(20000401)88:7<1590::AID-CNCR13>3.0.CO;2-C
Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity
K. Laitinen (2000)
Spindle-cell neuroendocrine carcinomas of the thymus (spindle-cell thymic carcinoid): a clinicopathologic and immunohistochemical study of seven cases.
C. Moran (1999)
10.1007/BF00185830
Functional histology of the human thymus
B. Gaudecker (1991)
Infrequent mutations of the p53 gene in pulmonary carcinoid tumors.
D. Lohmann (1993)
Bronchial carcinoid tumors: clinical and radiological correlation.
Antonella Squerzanti (2002)
10.1097/00000478-199812000-00004
Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
T. Kuo (1998)
10.1378/CHEST.119.4.1143
Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement.
C. Thomas (2001)
10.1016/J.ATHORACSUR.2005.11.067
Clinical value of the WHO classification system of thymoma.
F. Detterbeck (2006)
10.3779/j.issn.1009-3419.2010.06.005
[Retrospective study of clinicopathological characteristics in bronchopulmonary carcinoid].
Hongliang Liao (2010)
Medical progress : Carcinoid tumors
M. Kulke (1999)
10.1016/J.ATHORACSUR.2005.05.042
Does an anecdote substantiate dogma?
F. Detterbeck (2006)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1016/s0022-5223(19)36350-0
Results of surgical treatment for thymoma based on 66 patients.
S. Fujimura (1987)
10.1016/S0022-5223(94)70112-1
Thymic carcinoma. Ten years' experience in twenty patients.
Chung Ping Hsu (1994)
10.1148/radiology.142.1.7053522
Computed tomography of the abnormal thymus.
R. Baron (1982)
10.1002/(SICI)1096-9098(199609)63:1<17::AID-JSO4>3.0.CO;2-T
Preoperative radiotherapy and surgery for advanced thymoma with invasion to the great vessels.
E. Akaogi (1996)
Distribution of molecules mediating thymocyte-stroma-interactions in human thymus, thymitis and thymic epithelial tumors.
A. Marx (1994)
10.1200/JCO.2007.13.6374
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
J. Yao (2008)
10.1053/HUPA.2001.28245
Cytokeratin 7 and 20 and thyroid transcription factor 1 can help distinguish pulmonary from gastrointestinal carcinoid and pancreatic endocrine tumors.
Y. C. Cai (2001)
10.1016/0165-5728(94)00134-A
Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells
N. E. Gilhus (1995)
10.1016/S0360-3016(02)04150-0
Intensity-modulated radiotherapy following extrapleural pneumonectomy for the treatment of malignant mesothelioma: clinical implementation.
K. Forster (2003)
Surgical Pathology of the Mediastinum
A. Marchevsky (1991)
10.1148/RG.261055057
Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings.
S. Chong (2006)
10.1016/1010-7940(90)90140-U
Limited and radical resection for tracheal and bronchopulmonary carcinoid tumour. Report on 227 cases.
G. Stamatis (1990)
10.1002/1097-0142(19931001)72:7<2273::AID-CNCR2820720735>3.0.CO;2-U
Disseminated mediastinal carcinoma with chromosomal translocation (15;19). A distinctive clinicopathologic syndrome
A. Lee (1993)
10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4
Carcinoid Tumors An analysis of 2837 cases
J. Godwin (1975)
10.1002/1097-0142(19880615)61:12<2475::AID-CNCR2820611215>3.0.CO;2-5
Association of the epstein‐barr virus with lymphoepithelioma of the thymus
I. Dimery (1988)
10.1093/ANNONC/10.SUPPL_2.S23
Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
E. Krenning (1999)
10.1002/1097-0142(19921015)70:8<2077::AID-CNCR2820700811>3.0.CO;2-W
The distribution of epithelial membrane antigen in thymic epithelial neoplasms
I. Fukai (1992)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1159/000029231
Parathyroid-Hormone-Related-Protein-Producing Thymic Carcinoma Presenting as a Giant Extrathoracic Mass
K. Suzuki (1998)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar